// App-Quantinova.ai

Abstract 94 : Randomized, Double-blind, Placebo-controlled Phase 1 Study Of Vwf-binding Aptamer, Bb-031: Safety, Tolerability, Pharmacokinetic And Pharmacodynamic Activity In Healthy Volunteers

Researchers

Presenter

  • Shahid M Nimjee

Principal Investigators

  • Debra Wheeler

  • Stacy Nelson

  • Richard J Shea

  • Taegen Sullivan

  • Christina Mayer

  • Leo Pavliv

  • Juliana M Layzer

  • Jason Lickliter

  • Bruce Sullenger

  • Bruce Campbell

  • Richard C Becker

Medical Centers

  • The Ohio State Univerisity, Columbus, OH

  • Basking Biosciences, Inc, Columbus, OH

  • Cumberland Pharmaceuticals, Morrisville, NC

  • Nucleus Network, Melbourne, Australia

  • Royal Melbourne Hospital, Parkville, Australia

  • FinePoint Pharma, Durham, NC

  • Semivida Rsch, Dallas, TX

  • Regado Biosciences, Durham, NC

  • Duke Medcl Ctr, Durham, NC

  • University of Cincinnati, Cincinnati, OH

Locations

  • United States

  • Australia

Companies

  • N/A

Study Components

Therapeutic Area

  • Pulmonary/Respiratory Diseases

  • Cardiovascular (CVS)

  • Blood/haematological Diseases

Disease

  • Venous thrombosis

Biomarkers

  • von Willebrand factor

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Pharmacokinetics

  • Pharmacodynamics

  • Double Blind/Blinded

  • Controlled

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved